

**American College of Emergency Physicians
Clinical Policies Committee Meeting
July 21-22, 2022
Sonesta Denver Downtown, Denver, Colorado**

MINUTES

Participants

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Co-Chair; Deborah B. Diercks, MD, MSc, FACEP, Co-Chair; Richard Byyny, MD, MSc, FACEP, Methodologist (by phone); Stephen V. Cantrill, MD, FACEP, Liaison with Quality & Patient Safety Committee, and to the E-QUAL Steering Committee; Christopher R. Carpenter, MD, MSc, FACEP; John T. Finnell, MD, FACEP, FACMI, Board Liaison; Seth R. Gemme, MD, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH (by phone); Benjamin W. Hatten, MD, MPH, FACEP; Jason S. Haukoos, MD, MSc, FACEP, Methodologist; Amy Kaji, MD, MPH, PhD, Methodologist (by phone); Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP (by phone); Susan B. Promes, MD, MBA, FACEP; Kaushal H. Shah, MD, FACEP (by phone); Richard D. Shih, MD, FACEP (by phone); Andrea Slivinski, RN, DNP, ENA Representative (by phone); Molly E.W. Thiessen, MD, FACEP; Jonathan H. Valente, MD, FACEP (by phone); Melissa Villars, MD, MPH, EMRA Representative; Yanling Yu, PhD, Advocate for Patient Safety (by phone).

Also present for all or part of the meeting: Stephen Ducey, MD, Writing Committee on Stroke (by phone); Kelly Sarmiento, MPH, CDC Division of Injury Prevention, Writing Committee on Mild Traumatic Brain Injury (by phone); Jessica A. Whittle, MD, FACEP, Writing Committee on Sedation (by phone); Travis Schulz, MLS, AHIP, Staff Liaison; Kaeli Vandertulip, MSLS, MBA, AHIP, Staff Liaison.

Agenda

1. Welcome and introductions
2. Disclosures pertinent to the agenda
3. Subcommittee and liaison reports
4. 60-Day comments on mTBI clinical policy
5. Discuss stroke clinical policy draft
6. Discuss sedation clinical policy draft
7. Discuss potential questions for marijuana guideline
8. EMRA guideline update
9. Discuss naloxone policy statement draft
10. Discuss potential critical questions for carbon monoxide clinical policy

Major Points Discussed

1. Welcome and introductions

Dr. Diercks welcomed everyone to the meeting. Participants introduced themselves.

2. New disclosures pertinent to the agenda

There were no new disclosures pertinent to the agenda.

3. Subcommittee and liaison reports

Dr. Hatten informed the committee that he is working with the American College of Medical Toxicology (ACMT) and the European Society of Toxicology (EUROTOX) on a QT prolongation guideline.

Dr. Finnell provided a brief update on the 2022 ACEP Corporate Council meeting.

Dr. Promes informed the committee the paper on acute aortic aneurysm from the American Heart Association (AHA) should be published soon.

Dr. Carpenter informed the committee the Society for Academic Emergency Medicine (SAEM) GRACE program is initiating a guideline on low back pain. He also encouraged members to consider submitting policies to the new Cochrane open access journal.

Dr. Wolf updated the committee on his work with the American College of Radiology (ACR) on their Appropriateness Criteria topics.

Dr. Shih informed the group he is working on the ACEP/Society for Post-Acute and Long-Term Care Medicine (AMDA) ED guidelines collaboration on asymptomatic hypertension.

Dr. Slivinski (ENA Representative) provided updates from the Emergency Nurses Association.

4. 60-Day comments on mTBI clinical policy

Dr. Valente, with assistance from the writing committee members, led the committee members in the discussion of the comments received on the mTBI clinical policy during the 60-day open comment period. Recommendations were made for revisions to the draft based on the comments. The writing committee will incorporate the revisions into the draft.

5. Discuss stroke clinical policy draft

Dr. Lo led the conversation to review the stroke clinical policy draft. The committee suggested edits to the draft. The writing committee will incorporate the suggested changes and the committee will review the draft before it is posted for the 60-day open comment period.

6. Discuss sedation clinical policy draft

Dr. Thiessen, with assistance from the writing committee, led the conversation to review the sedation clinical policy draft. The writing committee will incorporate the suggested changes and the committee will review the draft.

7. Discuss the marijuana guideline

Dr. Hatten led the conversation to discuss the resolution to create a guideline on potential adverse effects of marijuana use. The committee agrees that hyperemesis, psychosis, and trauma caused by intoxication would be of greatest utility to emergency physicians. Dr. Carpenter shared that GRACE is currently working on a practice guideline for the treatment of hyperemesis. Because of the limited published data on this topic, the committee agrees that there would be more utility if

this was presented as a best practice document, such as a PREP, rather than as a guideline with consensus recommendations.

8. EMRA guideline update

Dr. Villars provided the guideline update for the 2021 American College of Chest Physicians “Clinical Guideline: Antithrombotic Therapy for Venous Thromboembolism.” Dr. Villars, with the assistance from Dr. Wolf, will prepare a summary of the guideline for *ACEP Now*.

9. Discuss naloxone policy statement draft

Dr. Shih led the discussion on the draft for the naloxone policy statement. The committee suggested edits to the draft. Dr. Shih will incorporate the suggested edits and present the changes to the writing committee for further input.

10. Discuss potential critical questions for carbon monoxide clinical policy

Dr. Shih led the discussion on the draft carbon monoxide critical questions. The committee discussed the draft questions. Travis will conduct a literature search for each of the three questions from the 2016 clinical policy. Members of the writing committee will review the literature to determine if any studies published since the last policy change the recommendations.